BioNTech SE (LTS:0A3M)

$ 107.65 -1.25 (-1.15%) Market Cap: 25.81 Bil Enterprise Value: 7.53 Bil PE Ratio: 0 PB Ratio: 1.23 GF Score: 63/100

Q3 2024 BioNTech SE Earnings Call Transcript
Nov 04, 2024

$110.65

Earnings
Q2 2024 BioNTech SE Earnings Call Transcript
Aug 05, 2024

$78 (-3.64%)

Earnings
Q1 2024 BioNTech SE Earnings Call Transcript
May 06, 2024

Earnings
Q4 2023 BioNTech SE Earnings Call Transcript
Mar 20, 2024

$88.32 (-6.15%)

Earnings
BioNTech SE at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
BioNTech SE Inaugurates its First African Site in Kigali Transcript
Dec 18, 2023
BioNTech SE Capital Markets Day Transcript
Nov 07, 2023
Q3 2023 BioNTech SE Earnings Call Transcript
Nov 06, 2023

$99.82 (+2.15%)

Earnings
Q2 2023 BioNTech SE Earnings Call Transcript
Aug 07, 2023

$96 (-10.64%)

Earnings
Q1 2023 BioNTech SE Earnings Call Transcript
May 08, 2023

$107.73

Earnings
Q4 2022 BioNTech SE Earnings Call Transcript
Mar 27, 2023

$125.08 (-2.55%)

Earnings
BioNTech SE at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 BioNTech SE Earnings Call Transcript
Nov 07, 2022

$155.93 (+2.84%)

Earnings
Q2 2022 BioNTech SE Earnings Call Transcript
Aug 08, 2022

$166.85 (-8.32%)

Earnings
BioNTech SE To Discuss on Host First Edition of Innovation Series on Diversified Pipeline, Latest Technology Innovations Call Transcript
Jun 29, 2022
Q1 2022 BioNTech SE Earnings Call Transcript
May 09, 2022

$144.9 (+5.71%)

Earnings
Q4 2021 BioNTech SE Earnings Call Transcript
Mar 30, 2022

$182.5 (+6.10%)

Earnings
BioNTech SE at JPMorgan Healthcare Conference Transcript
Jan 11, 2022
BioNTech SE To Discuss Hold Digital Press Conference to Provide an Update on Omicron Variant Call Transcript
Dec 08, 2021
Q3 2021 BioNTech SE Earnings Call Transcript
Nov 09, 2021

$235 (+0.86%)

Earnings
Q2 2021 BioNTech SE Earnings Call Transcript
Aug 09, 2021

$432 (+15.20%)

Earnings
BioNTech SE at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
BioNTech SE at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
BioNTech SE at UBS Global Healthcare Virtual Conference Transcript
May 26, 2021
Q1 2021 BioNTech SE Earnings Call Transcript
May 10, 2021

$197.5 (+10.34%)

Earnings
BioNTech SE at JPMorgan NAPA Valley Forum (Virtual) Transcript
Mar 31, 2021
Q4 2020 BioNTech SE Earnings Call Transcript
Mar 30, 2021

$106.16 (+10.80%)

Earnings
BioNTech SE at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 24, 2021
BioNTech SE at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Q3 2020 BioNTech SE Earnings Call Transcript
Nov 10, 2020

$108.77 (+4.75%)

Earnings
Q2 2020 BioNTech SE Earnings Call Transcript
Aug 11, 2020

Earnings
BioNTech SE To Present Early Positive Data From Ongoing Phase 1/2 Study of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript
Jul 01, 2020
BioNTech SE at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
BioNTech SE at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020
Q1 2020 BioNTech SE Earnings Call Transcript
May 12, 2020

Earnings
BioNTech SE - Special Call Transcript
Apr 23, 2020
Full Year 2019 BioNTech SE Earnings Call Transcript
Mar 31, 2020

Earnings
BioNTech SE at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 BioNTech SE Earnings Call Transcript
Nov 14, 2019

Earnings

Q1 2022 BioNTech SE Earnings Call Transcript

May 09, 2022 / 12:00PM GMT

Release Date Price: $144.9 (+5.71%)

Transcript

Operator

Welcome to the BioNTech First Quarter 2022 Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas. Please go ahead, Sylke.

Sylke Maas

BioNTech SE - VP of IR and Business Strategy

Good morning and good afternoon, and thank you for joining us today to review BioNTech's First Quarter 2022 Clinical and Operational Progress and Financial Results. A few housekeeping items before we start. Please view the slides that accompany the webcast in the first quarter 2022 press release, both were issued this morning and can be found in the Investors section of our website.

As outlined on Slide 2, today's presentation, we'll be making several forward-looking statements. These forward-looking statements include, but are not limited to, our current COVID-19 vaccine revenues as they include figures that are derived from preliminary estimates provided by our partners, our estimated financial results for 2022, the continued global demand for our COVID-19 vaccine, our target vaccine production capacity for 2022

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.